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Background: Self-assembled mannan nanogels are designed to provide a therapeutic or vaccine delivery plat-
form based on the bioactive properties of mannan to target mannose receptor expressed on the surface of
antigen-presenting cells, combined with the performance of nanogels as carriers of biologically active agents.
Methods: Proteins in the corona around mannan nanogel formed in human plasma were identiﬁed by mass
spectrometry after size exclusion chromatography or centrifugation followed by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis. Structural changes and time dependent binding of human apolipoprotein A-I
(apoA-I) and human serum albumin (HSA) to mannan nanogel were studied using intrinsic tryptophan ﬂuo-
rescence and circular dichroism spectroscopy. The mannan nanogel effect on blood coagulation and ﬁbrilla-
tion of Alzheimer's disease-associated amyloid β peptide and hemodialysis-associated amyloidosis β2
microglobulin was evaluated using thrombin generation assay or thioﬂavin T ﬂuorescence assay, respectively.
Results: The protein corona around mannan nanogel is formed through a slow process, is quite speciﬁc com-
prising apolipoproteins B-100, A-I and E and HSA, evolves over time, and the equilibrium is reached after
hours to days. Structural changes and time dependent binding of apoA-I and HSA to mannan nanogel are
minor. The mannan nanogel does not affect blood coagulation and retards the ﬁbril formation.
Conclusions: Mannan nanogel has a high biosafety and biocompatibility, which is mandatory for nanomaterials
to be used in biomedical applications.
General Signiﬁcance:Our research provides amolecular approach to evaluate the safety aspects of nanomaterials,
which is of general concern in society and science.© 2012 Elsevier B.V. All rights reserved.1. Introduction
Nanometer-sized polymeric hydrogels, i.e. nanogels, combine favor-
able and exceptional properties, such as ﬂexible size in the nanometer
range, tunable chemical and physical structures, large surface areas for
multivalent conjugation, high water content, and biocompatibility
[1,2]. Nanogels represent a promising class of delivery devices for bio-
logically active agents because of their loading capacity, their stability,
as well as their responsiveness to environmental factors [1].
A self-assembled mannan nanogel has been designed and charac-
terized in our group as a potential multifunctional nanosized device
for biomedical applications [3]. The mannan nanogel is spherical
and polydisperse with a mean hydrodynamic diameter between 50
and 140 nm, and has a slightly negative surface charge [3].+351 253604429.
erreira),
ski@biochemistry.lu.se
ohm),
ail.com (S. Linse),
.com (T. Cedervall).
rights reserved.Mannose receptor, expressed in the surface of antigen-presenting
cells [4–7], was previously shown to take part in host defense, providing
a linkage between innate and adaptive immunity [7–10]. The choice of
mannan as the main component of the nanogel aims to take advantage
of the association of the bioactive properties ofmannanwith the perfor-
mance of nanogels as carriers of biologically active agents. The mannan
nanogel is thus suggested as a possible tool for vaccine formulations,
acting as an adjuvant suitable to induce a protective and long-lasting
immune response, or as a targeted therapeutic delivery system to be
used for the treatment of macrophage associated pathologies.
Nanoparticles, including nanogels, will interact with proteins in a
biological environment creating an outer layer around the particle
known as the protein corona [11,12]. The proteins are the most stud-
ied substances in the corona but it can include other biomolecules, for
example lipids [13]. The composition and surface chemistry of a spe-
ciﬁc nanoparticle will dictate the extent and speciﬁcity of protein
binding [12]. Surface charge, hydrophobicity, particle size, morpholo-
gy, shape and surface curvature of nanoparticles affect what proteins
bind to the nanoparticle [11,12,14–20]. The composition of the pro-
tein corona on a given nanoparticle, at a given time, will depend on
the protein concentrations in the physiological ﬂuid and the on- and
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identity of the nanoparticle, will change with time [20–24] and with
environmental changes [24,25], for example, when nanoparticles
travel from blood to inside cells [25]. The protein corona will be im-
portant for the biocompatibility and biosafety. Proteins on the nano-
particle surface can interact with blood proteins and cell receptors,
and consequently affect uptake and intracellular fate [24,26–32], bio-
distribution of the nanomaterials throughout the body, toxicity and/
or efﬁcacy [14,15,33–35].
When proteins bind to nanoparticles a structural change in the pro-
tein often occurs [16,36]. It has been proposed that these structural
changes, in addition to the protein composition in the corona, may
lead to changed biological functions and consequently be important
for evaluating the biosafety of nanoparticles [14,30,36]. Recent reports
describe how changes in the corona can mediate the biological impact
of the nanoparticles. Fibrinogen bound to poly(acrylic acid)-coated
gold nanoparticles undergo a structural change that can facilitate inter-
action and activation of MAC-1 receptor pathway on macrophage-like
cells and subsequent inﬂammation response [37]. Enzyme activity can
be enhanced and stabilized over time when bound to nanoparticles
[38]. The opposite is also true as trypsin immobilized on silica and poly-
styrene nanospheres [39], or lysozyme andα-chymotrypsin [40] bound
to gold nanoparticles experienced a large structural change, and the en-
zymes lost their activity. On most studied spherical particles, apolipo-
proteins are identiﬁed in the corona formed in human blood plasma
[11]. They suffered a structural change after binding to polystyrene par-
ticles [41]. Apolipoproteins are central in the fatmetabolism and uptake
of apolipoprotein binding polystyrene particles through a feeding web
could cause severe metabolic and behavioral disturbances in ﬁsh [42].
Proteins important for the initiation and regulation in the coagula-
tion cascade have been identiﬁed in the corona from polystyrene [20],
citrate-capped gold [24], and silica nanoparticles [25]. Recent results
in our laboratory have shown that amine-modiﬁed polystyrene
nanoparticles inhibited coagulation by speciﬁc interactions with two
coagulation factors and that in opposite carboxyl-modiﬁed polysty-
rene nanoparticles activated the coagulation [43]. It is highly relevant
to test particle destined to circulate in the body for its effect on the co-
agulation cascade because disorders of coagulation can lead to an in-
creased risk of bleeding (hemorrhage) or obstructive clotting
(thrombosis). The ﬂuorometric thrombin generation assay is pro-
posed as a good method to evaluate the procoagulant activity of
nanomaterials in human plasma and has been used to study the
procoagulation effects caused by several nanoparticles [44].
Protein aggregation can lead to major disturbances of cellular pro-
cesses and is associated with several diseases. Proteins may under cer-
tain conditions and as a function of time give up their natively folded
state and form amyloid ﬁbrils [45,46]. Human amyloid diseases involve
self-assembly of soluble proteins into large insoluble ﬁbrils through
nucleation-dependent assembly, often via the formation of oligomeric
structures that possess toxic properties [47,48]. The ﬁbrillation of amy-
loid proteins and peptides as Alzheimer's disease-associated amyloid β
peptide (Aβ(M1-40)) found in brain lesions and hemodialysis-associ-
ated amyloidosis β2 microglobulin (β2m) are well studied.
Nanomaterials [46], such as nanogel formed by self-aggregation of
cholesterol-bearing pullulan with molecular chaperone-like activity
[49] and N-isopropylacrylamide:N-tert-butylacrylacrylamide (NIPAM:
BAM) nanoparticles [50], have been linked to Aβ ﬁbrillation retarda-
tion. In contrast, NIPAM:BAM nanoparticles caused acceleration of
β2mﬁbrillation [51]. Also, at constant Aβ(M1-40) concentration, the ﬁ-
brillation process was accelerated by amino-modiﬁed polystyrene
nanoparticles at low concentration, while at high nanoparticle concen-
tration, the ﬁbrillation process was retarded [52].
In the present work, the protein corona around mannan nanogel
in human plasma was characterized to evaluate its biosafety and bio-
compatibility from a molecular perspective. Proteins in the corona
were identiﬁed by mass spectrometry after gel ﬁltration using sizeexclusion chromatography (SEC) or centrifugation followed by sodi-
um dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Time dependence and structural changes of human apolipoprotein
A-I (apoA-I) and human serum albumin (HSA) binding to mannan
nanogel were studied using intrinsic tryptophan ﬂuorescence and cir-
cular dichroism (CD) spectroscopy. The mannan nanogel effect on
blood coagulation was evaluated by ﬂuorometric thrombin genera-
tion assay. The role of mannan nanogel in protein ﬁbrillation was
evaluated by continuous thioﬂavin T (ThT) ﬂuorescence assay using
both Aβ(M1-40) and β2m.
2. Material and methods
2.1. Materials
Mannan-VMA-SC16 (VMA: vinyl methacrylate, SC16: hydrophobic
alkyl chain) was synthesized as described previously [3] with 31 ac-
rylate groups (DSVMA 31%) and 20 alkyl chains (DSC16 20%) per 100
mannose residues. Resultant amphiphilic mannan is named as
MVC16-31-20. With DSC16/DSVMA equal to 65%, it has critical aggre-
gation concentration (cac) or critical micelle concentration (cmc)
equal to 0.01 mg/mL [3]. Human donors' plasma from lipidemic pa-
tients was obtained from the local hospital blood bank and pre-
served in aliquots at −80 °C. Before each experiment aliquots
were defrosted and centrifuged for 2 min at 14,927g (Biofuge 13,
Heraeus) and immediately used after rejecting the top lipid layer.
ApoA-I was puriﬁed from human plasma as previously described
[53]. HSA (Sigma, A3782, fatty acid free, 99% pure) was puriﬁed
from dimer and contaminating proteins using gel ﬁltration on a
200×3.4 cm Sephadex G50 column in 50 mM ammonium acetate
buffer, pH 6.5. Fractions containing HSA monomer were pooled, ly-
ophilized and desalted by gel ﬁltration on a G25 Sephadex super-
ﬁne column in Millipore water. ApoA-I and HSA stock solutions
(10 mg/mL) were dialyzed for 5 days against frequently changed
phosphate buffered saline pH 7.5 (PBS) at 4 °C using twice boiled
in distilled water regenerated cellulose tubular membranes, with
6000–8000 nominal MWCO, obtained from Membrane Filtration
Products. Phospholipids were obtained from Avanti Polar Lipids,
Inc. (Alabaster, AL, USA). Recombinant tissue factor was obtained
from Dade Innovin (Marburg, Germany). The thrombin ﬂuorogenic
substrate I-1140 (Z-Gly-Gly-Arg-7-amino-4-methylcoumarin∙HCl)
was purchased from Bachem (Bubendorf, Switzerland). Aβ(M1-40)
was expressed in Escherichia coli and puriﬁed as previously de-
scribed [54]. β2m was expressed in E. coli and puriﬁed as previous-
ly described [51]. Organic and inorganic reagents of laboratory
grade were purchased from Sigma-Aldrich and used without any
further puriﬁcation, unless otherwise stated. Water was puriﬁed
with a Milli-Q system (Millipore Corporation).
2.2. Mannan nanogel preparation
Colloidal dispersions of amphiphilic mannan were prepared stir-
ring the lyophilized MVC16-31-20 in PBS, for 3–5 days at 50 °C,
followed by ﬁltration (Orange; pore size 0.22 μm). The nanogel for-
mation was conﬁrmed by dynamic light scattering (DLS; Malvern
Zetasizer NANO ZS—Malvern Instruments Limited, UK) as previously
described [3]. The colloidal dispersion of nanogel (2 mg/mL) showed
z-average equal to 154.1±5.625 nm and polydispersity index (PdI) of
0.229±0.007.
2.3. Gel ﬁltration of mannan nanogel and plasma proteins
Plasma (250 μL) was incubated with mannan nanogel (800 μL at
2 mg/mL) or with PBS (800 μL; control) stirring for 24 h at 37 °C.
Samples were separated by SEC on a 100×1 cm Sephacryl 1000 col-
umn. The absorbance of all fractions was recorded at 280 nm in UV-
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22 to 37 pooled from four different experiments were precipitated
with trichloroacetic acid 10% and frozen at −20 °C. Samples were
centrifuged 15 min at 14,927g (Heraeus Kendro Biofuge 13), and the
pellet was washed with ice cold acetone. Pellets were resuspended
in 5 μL of PBS, and proteins were desorbed from the nanogel by
adding 10 μL of sodium dodecyl sulfate (SDS) loading buffer and incu-
bated for 5 min at 95 °C. Samples were separated by SDS-PAGE, with
resolving gel 15% and stacking gel 4%. Each gel run included one lane
of a molecular weight ladder standard, PageRuler Prestained Protein
Ladder (Fermentas). Gels were Coomassie stained. All fractions resul-
tant of SEC separation of nanogel alone had similar absorbance to that
obtained with the PBS at 280 nm.
2.4. Identiﬁcation of corona proteins using centrifugation and mass
spectrometry
Colloidal dispersions of mannan nanogel in PBS (100 μL; 0, 0.1,
0.25, 0.5, 0.75, 1 or 2 mg/mL) were incubated stirring with plasma
or PBS (100 μL) for 1 and 24 h at 37 °C. Colloidal dispersions of man-
nan nanogel in PBS (100 μL; 2 mg/mL) were incubated stirring with
increasing amount of plasma (50 μL, 100 μL, 200 μL, 400 μL or
800 μL; in a ﬁxed ﬁnal volume), for 1 and 24 h at 37 °C. Samples
were centrifuged 15 min at 19,873g (Heraeus Kendro Biofuge 15),
and the pellet was washed twice with 500 μL PBS changing the vial
after each washing step. Samples were separated by SDS-PAGE and
Coomassie blue stained as described above. Each experiment was per-
formed twice. Gels were preserved in 1% acetic acid in water at 4 °C
for mass spectrometry. Bands were excised from the gel, reduced,
alkylated, and digested with trypsin (Sequencing Grade Promega,
Madison, WI), and the resulting peptide mixtures were analyzed by
MALDI-TOF mass spectrometry using a 4700 Proteomics Analyzer
(Applied Biosystems, MA) mass spectrometer in positive reﬂector
mode. Both MS and tandem MS (MS/MS) spectra were analyzed by
Matrix Science Mascot software to identify tryptic peptide sequences.
2.5. Circular dichroism spectroscopy
ApoA-I or HSAwere incubated stirring at 37 °C in the absence and
in the presence of the mannan nanogel at various concentrations in
PBS. CDmeasurements were carried out using a JASCO J-815 spectro-
polarimeter (JASCO, Easton, MD) with a Peltier type thermostated
cell holder. Far-UV CD spectra (190–260 nm) were recorded at
37 °C in continuous mode with a scan rate of 50 nm/min and a digital
integration time of 8 s using 0.1 cm quartz cuvettes with a Teﬂon
stopper. Three spectra were accumulated and averaged for each
sample. The average spectra for a blank (colloidal dispersion of man-
nan nanogel – Fig. S1A in Supplementary data – or buffer) were sub-
tracted from the spectrum of each protein sample. The conformation
of protein in the absence and in the presence of the nanogel was es-
timated from CD spectra. This experiment was performed at least
twice.
2.6. Intrinsic tryptophan ﬂuorescence
ApoA-I or HSA were incubated stirring at 37 °C in the absence and
the presence of the mannan nanogel at various concentrations in PBS.
Fluorescence measurements were performed on a luminescence spec-
trometer LS 50B (PerkinElmer) with a cuvette holder thermostated at
37 °C. Fluorescence emission spectra (310–460 nm) were recorded at
an excitation wavelength of 290 nm with a scan rate of 100 nm/min.
Three spectra were accumulated and averaged for each sample.
Reported average spectra are those after the subtraction of the spec-
trum for a blank (colloidal dispersion of mannan nanogel – Fig. S1B in
Supplementary data – or buffer) from the spectrum of each protein
sample. Also ﬂuorescence emission spectra of a colloidal dispersion ofmannan nanogel (0.6 mg/mL) with ApoA-I or HSA (0.1 mg/mL) were
recorded over time at 37 °C. These experiments were performed at
least twice.2.7. Thrombin generation assay
The amount of thrombin formed in plasma/mannan nanogel
samplesweremonitored using the thrombin generation assay as previ-
ously described [55] with the following modiﬁcations. Natural phos-
pholipids, 20–20–60 phosphatidylserine–phosphatidylethanolamine–
phosphatidylcholine (PS–PE–PC), were mixed and prepared. Citrate
platelet poor plasma (40 μL) was preincubated with 40 μL of 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered
saline (HBS, 10 mM HEPES, 150 mM NaCl, pH 7.4) or mannan nanogel
(ﬁnal concentration of 1 mg/mL) at 37 °C for 15 min. Fluorogenic
substrate (Z-Gly-Gly-Arg-7-amino-4-methylcoumarin∙HCl; 20 μL) was
added to samples and coagulation was initiated with 20 μL of phospho-
lipids/tissue factor/CaCl2 mixture in a ﬁnal volume of 120 μL. All re-
agents were diluted in HBSBSA (HBS buffer supplemented with 5 mg/
mL of bovine serum albumin (BSA)), and ﬁnal concentrations were
approximately 1.17 pM tissue factor, 4.2 μM phospholipids, 300 μM
ﬂuorogenic substrate and 16 mM CaCl2. Fluorescence measurements
over time were taken in black ﬂat bottom 96-well plates (Nalge Nunc
International, Rochester, NY, USA) in a plate Tecan Inﬁnite 200 ﬂuo-
rometer equipped with a 360 nm excitation/460 nm emission ﬁlter
set (Mölndal, Sweden) and Magellan software (Gröedig, Austria).2.8. Thioﬂavin T ﬂuorescence assay
Peptide Aβ(M1-40) samples in 20 mM sodium phosphate buffer
pH 7.4, 200 μM ethylenediaminetetraacetic acid (EDTA), 0.02% NaN3
or protein β2m samples in 20 mM sodium phosphate buffer pH 2.5,
50 mM NaCl, 0.02% NaN3, were pipetted into wells of a 96-well half-
area plate of black polystyrene with a clear bottom and polyethylene
glycol coating (Corning 3881), 50 μL per well, which contained either
50 μL of respective buffer or 50 μL of mannan nanogel in respective
buffer, resulting in ﬁnal 10 μM Aβ(M1-40) or 40 μM β2m concentra-
tions and ﬁnal nanogel concentrations between 0.001 mg/mL and
0.9 mg/mL. All samples were supplemented with 20 μM ThT. Plate
was sealed with a plastic ﬁlm (Corning 3095). The nanogel size was
not affected in the buffers used as conﬁrmed by DLS. Fibrillation of
Aβ(M1-40) and of β2m at 37 °C was monitored by the temporal de-
velopment of ThT binding in the absence and in the presence of man-
nan nanogel at 0.001–0.9 mg/mL.
The experiment was initiated by placing the 96-well plate at 37 °C
and shaking at 100 rpm in a plate reader (Fluostar Omega, BMGLabtech,
Offenburg, Germany). The ThT ﬂuorescence was measured through the
bottom of the plate every 6 min (with excitation ﬁlter 440 nm and
emission ﬁlter 480 nm) with continuous shaking at 100 rpm between
reads. The ThT ﬂuorescence was followed for two different 96-well
plates (one plate with 8 samples for Aβ(M1-40) and β2m in
pentaplicate, and another plate with 8 samples for Aβ(M1-40) and
β2m in hexaplicate) yielding in total 11 kinetic traces per sample. Con-
trols that ran with only nanogel with ThT showed that the nanogel did
not interfere with the assay. The dye selectively binds to amyloid ﬁbrils
with an accompanying increase in ﬂuorescence intensity [56,57]. Inter-
action of amyloidﬁbrils and protoﬁbrils with ThT causes a red shift in its
excitation spectrum [58], and ThTﬂuorescence is therefore ameasure of
ﬁbrillogenesis. The kinetics aggregation data have a sigmoidal appear-
ance and exhibits characteristics of a typical nucleation-dependent po-
lymerization and growth process. The time course of ﬁbrillogenesis
includes a lag phase duringwhich the concentration of ThT-positive ag-
gregates is too low to be detected followed by a rapid exponential
growth (elongation) of ﬁbrils [59,60].
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3.1. Apolipoprotein corona around mannan nanogel
Samples of mannan nanogel incubated with human plasma for
24 h at 37 °C were separated by SEC. Two distinct peaks are seen in
the elution proﬁle (Fig. 1A upper panel). The major peak that elutes
at fraction 71 is also found in SEC of plasma only and corresponds
to the elution of unbound proteins. A minor peak elutes at around
fraction 26. This peak is not seen in experiments with plasma only
and likely corresponds to mannan nanogel associated with plasma
proteins. In order to characterize the proteins associated with the
nanogel, individual fractions 22 to 37 from four different experiments
were pooled, precipitated with trichloroacetic acid and the proteins
visualized by Coomassie blue after separation by SDS-PAGE (Fig. 1A
middle panel). Several proteins are found in the precipitated frac-
tions. In control experiments without mannan nanogel no proteinsFig. 1. Protein corona around mannan nanogel. Colloidal dispersion of mannan nanogel in P
arated by size exclusion chromatography: average absorbance at 280 nm of collected fract
circles) of nanogel (upper panel A); Coomassie stained gels of plasma proteins associated w
individual fractions 22 to 37 pooled from four different experiments, precipitated with tric
nanogel after 1 h (B) and 24 h (C) of incubation stirring at 37 °C of constant amount of manare found in fractions 22 to 37 (Fig. 1A lower panel), which strongly
indicates that these proteins are associated and co-elute with the
nanogel. The protein proﬁle of human plasma is shown in Fig. S3 in
Supplementary data, and clearly it is different from the proﬁle of plas-
ma proteins associated with mannan nanogel. One protein with a mo-
lecular weight around 68 kDa is seen in all fractions when nanogel is
added. This is likely to be HSA, which is the most prominent protein
in plasma (about 35 mg/mL). The high concentration of HSA means
that even if it binds to the nanogel with low afﬁnity it is likely to
co-elute and continuously detach from the nanogel over the elution
time.
Another common way to separate particles with bound proteins
from unbound proteins is by centrifugation. The mannan nanogel was
mixed with human plasma and incubated 1 h at 37 °C. The mixture
was centrifuged, the pellets washed and bound proteins dissolved in
buffer with SDS and separated by SDS-PAGE (Fig. 1B). Several proteins
are co-pelleted with the nanogel indicating that they are bound to theBS incubated with human plasma for 24 h at 37 °C or pure plasma as control were sep-
ions of loaded human plasma in the absence (open circles) or in the presence (closed
ith the nanogel (middle panel A) and control with only plasma (lower panel A), within
hloroacetic acid. Coomassie stained gels of plasma proteins co-pelleted with mannan
nan nanogel and increasing amount of plasma from left to right, in a ﬁxed ﬁnal volume.
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centrations, or higher concentration of plasma produced larger pellets
during centrifugation experiments. No pelleted proteins were seen in
experiments without nanogel (data not shown). Nanogel in buffer
will not pellet at the same centrifugation speed showing that the densi-
ty and/or aggregation properties of the mannan nanogel are changed
after plasma proteins have bound. To identify the bound proteins, the
ﬁvemajor protein bandswere cut out froma similar SDS-PAGE, the pro-
teins digested with trypsin and the peptides subjected to mass spec-
trometry. The ﬁve major proteins after 1 h of incubation are identiﬁed
as apolipoproteins B-100, A-I and E, and HSA (Fig. 1B). One major pro-
tein band with an apparent molecular weight of 55 kDa is unidentiﬁed.
This is a comparably simple protein corona. Most studied nanoparticles
have a much more complex protein corona with a wide variety of pro-
teins. One particle, the NIPAM:BAM copolymer, has a protein corona
withmainly apolipoproteins, but without B-100 [11,12]. It would be in-
teresting to compare the inﬂuence on the biocompatibility of the corona
for these two materials with other nanoparticles.
A comparison of the bound proteins isolated by SEC and centrifu-
gation, after incubation for 1 or 24 h, shows not only several similar-
ities but also differences. The ﬁve major proteins are present in all
conditions, but the ratios between the proteins are different. In the
centrifugation experiments, apolipoproteins B-100 and A-I are the
dominating proteins but after 24 h the ratio between HSA and apoli-
poproteins is larger than after 1 h of incubation (Fig. 1B and C). This
change in ratios is more pronounced in SEC in which mannan nanogel
also was incubated for 24 h in plasma before separation. In SEC exper-
iments there is an extra major protein band around 50 kDa. This pro-
tein band also appears in centrifugation after 24 h of incubation but in
much smaller amounts. These differences in the corona between 1Fig. 2. Far-UV CD (A and C) and tryptophan ﬂuorescence emission (λex=290 nm) (B and D
dispersion of mannan nanogel in PBS at 0.5 mg/mL (gray solid line) and at 1 mg/mL (black s
B) shows spectra recorded with apoA-I at 0.1 mg/mL, and the right panel (C and D) showsand 24 h indicate that the corona is formed through a slow process
and that equilibrium is reached only after a long time. A time depen-
dent corona has been observed for sodium citrate stabilized gold
nanoparticles [22,24]. It was also shown that cell uptake of particles
was different depending on the time particles were incubated in
media before adding to the cells [61]. Consequently, time may be an
important factor for how mannan nanogel interacts with the sur-
rounding ﬂuids and tissues after administration into the body.
3.2. Structural consequences of apoA-I and HSA binding to mannan
nanogel
Protein binding to nanoparticles is often accompanied by a struc-
tural change in the proteins [16,37,41,62]. Two proteins in the corona
around mannan nanogel, apoA-I and HSA were chosen for further
analysis of the protein structure after binding to the nanogel. CD spec-
troscopy was used to follow changes in the secondary structure of the
proteins. The CD spectrum of apoA-I has two minima at 222 and
208 nm, which are characteristic of the α-helical structure (Fig. 2A).
After adding mannan nanogel to apoA-I the negative signal at 222
and 208 nm is stronger, indicating an increase or stabilization of the
α-helical structure. Also HSA has α-helical structure, but for HSA
there are no signiﬁcant changes in the structure after adding nanogel
(Fig. 2C).
Intrinsic tryptophan ﬂuorescence spectroscopy is used to follow
changes in the tertiary structure of the proteins. The ﬂuorescence
spectra of apoA-I and HSA have maxima at 340 and 344 nm, respec-
tively (Fig. 2B and D) indicating a folded protein structure in which
the tryptophan side chain is buried in a hydrophobic internal envi-
ronment. Adding mannan nanogel to the apoA-I causes a decreased) spectra of protein in the absence (black dashed line) or in the presence of a colloidal
olid line) recorded at 37 °C after 1 h of incubation stirring at 37 °C. The left panel (A and
spectra recorded with HSA 0.2 mg/mL.
Fig. 4. The effect on thrombin generation by mannan nanogel. Plasma was incubated in
the absence (solid line) or in the presence (dashed line) of a colloidal dispersion of
mannan nanogel at 1 mg/mL, and tested for thrombin generation using the thrombin
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tryptophan side chain is buried in the interface between the protein
and nanogel after protein binding. Addingmannan nanogel to HSA in-
duces, in addition to the decrease in intensity, a blue shift in the
wavelength maximum, indicating that the environment around the
tryptophan side chains is more hydrophobic after binding to the
nanogel.
ApoA-I is the main protein in high-density lipoprotein (HDL) par-
ticle and central in the lipid metabolism. A structural change in the
protein altering the function of apoA-I could thereby inﬂuence the
lipid metabolism in a potential harmful way. An increase of helical
structure in apoA-I is also seen when it binds to phospholipids in
HDL [63–65]. The structural change seen in both cases may be caused
by stabilization of the protein structure normally occurring when
apoA-I binds to a spherical surface.generation assay. The ﬁrst derivative, ﬂuorescence units/min, is shown (average,
n=3).
Fig. 3. Time dependent binding of apoA-I (black) and HSA (gray) at 0.1 mg/mL to man-
nan nanogel at 0.6 mg/mL in PBS at 37 °C. Normalized tryptophan emission intensity
(λex=290 nm) at 345 nm as function of time (A). Fluorescence titration of apoA-I
(black) and HSA (gray) solutions at 0.1 mg/mL in the presence of colloidal dispersions
of mannan nanogel at various concentrations in PBS after stirring 1 h (open circles) and
24 h (closed circles) at 37 °C. Normalized ﬂuorescence intensity at 345 nm as function
of mannan nanogel concentration (B).3.3. Time dependent binding between apoA-I and mannan nanogel
The centrifugation experiments in human plasma showed that ra-
tios between proteins in the corona change over time. In general this
is expected as predicted by the Vroman effect; proteins present at
high concentration in plasma will bind ﬁrst but will be replaced
over time by proteins with lower concentrations but higher afﬁnity.
However, for mannan nanogel also the total amount of proteins in
the corona appeared to be lower after 24 h compared to after 1 h. A
plausible scenario is that the proteins and/or the mannan nanogel
structures are changed slowly over time whereby the time to reach
equilibrium will be many hours. One such scenario could be that the
proteins with time enter the nanogels and interact with the hydro-
phobic domains inside the nanogels. To test if the proteins' structural
change is time dependent, the intrinsic tryptophan ﬂuorescence was
measured after 1 and 24 h. A clear difference in intensity is seen for
apoA-I, but not for HSA after 1 and 24 h of incubation with nanogel
(Fig. S2 in Supplementary data). To further characterize the time de-
pendency, the intensity from the proteins in the presence of nanogel
at 0.6 mg/mL was obtained at different time points (Fig. 3A). The in-
tensity from HSA is constant while the intensity from apoA-I de-
creases over time. The most prominent change takes place within
1 h, but the intensity continues to decrease for several hours indicat-
ing that the process of apoA-I binding to the nanogel is slow. The af-
ﬁnity of the binding is compared by measuring the intensity at
345 nm after 1 h (open circles) and 24 h (closed circles) for apoA-I
(black circles) and HSA (gray circles) in increasing concentrations of
mannan nanogel (Fig. 3B). The intensity decreases with increasing
concentrations of nanogel for both apoA-I and HSA. No differences
are seen between the titration curves for HSA after 1 and 24 h, and
at high concentrations of nanogel the intensity is constant indicating
that all proteins are bound to the nanogel. In contrast there is a strik-
ing difference between the titration curves after 1 and 24 h of incuba-
tion of nanogel and apoA-I. The intensity decreases more at nanogel
concentrations over 0.3 mg/mL after 24 h of incubation than after
1 h, indicating that more proteins are bound to the nanogel or that
a different structural change has occurred after 24 h of incubation.
As the estimated amount of apoA-I on the particle is lower after
24 h than after 1 h of incubation (Fig. 1B) the explanation that
apoA-I undergoes a slow structural change, which may involve inter-
actions with hydrophobic domains inside the mannan nanogel, is
more plausible. The stability in size of nanogel over time was tested
by measuring the mean hydrodynamic diameter of the mannan
nanogel in the presence and in the absence of HSA (Fig. S4 in Supple-
mentary data). No signiﬁcant changes were observed indicating that
the nanogel is stable over the time frame of the measurement. The
time dependent structural changes that were seen in the corona
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over time.
Attempts were made to estimate the afﬁnity from the titration ex-
periments. The dissociation constant (KD) of HSA-nanogel complex is
estimated to be in μM range (not shown). A similar value of KD, 6 μM,
was obtained by isothermal titration calorimetry (Fig. S5 in Supple-
mentary data), indicating that HSA binds with low afﬁnity to the
mannan nanogel. The apoA-I data could not be ﬁtted using Langmuir
equation. Low afﬁnity of albumin binding has been observed for other
nanoparticles NIPAM:BAM copolymer, 0.83 μM [66]; 20 nm gold,
2.5 μM [62]; and polystyrene, 1.2 μM [41]. The low afﬁnity, compared
to for example the higher afﬁnity, 1 nM, of apoA-I to NIPAM:BAM co-
polymer [21], explains why only small amount of HSA is found on the
particles although the plasma concentration is high.3.4. Mannan nanogel does not affect blood coagulation
The effect on blood coagulation by mannan nanogel was tested by
the thrombin generation assay. No inhibition or stimulation of the
thrombin generation is seen when mannan nanogel is added to the
system (Fig. 4). In another study, using the same assay, amine-
modiﬁed polystyrene nanoparticles (0.5 mg/mL) inhibited the
thrombin generation whereas 220 nm carboxyl-modiﬁed polystyrene
nanoparticles (0.5 mg/mL) promoted the thrombin generation [43].
Several other nanoparticles can act as procoagulants in the same
assay, for example carbon black, silicon dioxide, silicon carbide, titani-
um carbide and copper oxide nanoparticles [44]. As shown above theFig. 5. Fibrillation of Aβ(M1-40) (A and B) and of β2m (C and D) at 37 °C monitored by the t
tion of time for 10 μMAβ(M1-40), in 20 mM sodium phosphate buffer pH 7.4, 200 μM EDTA,
0.02% NaN3 (C), in the absence (dash line) or in the presence (solid line) of mannan nanoge
representative experiment are shown. Half-time of ﬁbrillation (t1/2) as function of the log of
bars indicate the standard deviation of the average of 11 replicates, 5 and 6 of two indepenprotein corona around mannan nanogel is, in contrast to most other
nanoparticles studied, simple and consists mainly of apolipoproteins.
For NIPAM:BAM copolymer nanoparticles, however, a similar protein
corona of apolipoproteins was described [11,12]. An increase of the
more hydrophilic NIPAM part leads to decreased amount of proteins
bound, but that did not change the identity of the proteins [11,12].
To compare two different polymer particles with similar protein coro-
na, NIPAM coated gold nanoparticles were tested by the thrombin
generation assay (Fig. S6 in Supplementary data). No stimulation of
the coagulation was seen. Maybe a simple corona of apolipoproteins
is less prone to stimulate the coagulation and is a sign of biocompat-
ibility from a coagulation perspective.
3.5. Mannan nanogel retards Aβ(M1-40) and β2m ﬁbrillation
The formation of amyloid aggregates was studied in the absence
and in the presence of mannan nanogel using a continuous ThT bind-
ing assay. A signiﬁcant increase in ThT ﬂuorescence was observed
over time, suggesting amyloid ﬁbrils are formed both with and with-
out nanogel present. However, the presence of mannan nanogel leads
to a slight retardation of both Aβ(M1-40) and β2m ﬁbrillation at
nanogel concentrations in the range 0.03–0.9 mg/mL where the ag-
gregation is delayed by at most a factor of two–three (Fig. 5). An im-
portant result is that under no conditions do we see any acceleration
of aggregation as has been observed for other nanoparticles [49,50].
Thus it appears that the nanogel acts to reduce the rate of nucleation,
but the elongation rate is essentially unaffected by the presence of the
nanogel. At constant Aβ(M1-40) and β2m concentration, the timeemporal development of thioﬂavin T (ThT) binding. ThT ﬂuorescence intensity as func-
0.02% NaN3 (A) or 40 μM β2m, in 20 mM sodium phosphate buffer pH 2.5, 50 mM NaCl,
l at 0.03 mg/mL, as an example. Each sample contained 20 μM ThT. Five replicates of a
mannan nanogel concentration (0–0.9 mg/mL) for Aβ(M1-40) (B) and β2m (D). Error
dent experiments.
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increases with the increase in mannan nanogel concentration
suggesting that the formation of ﬁbrils is delayed by interaction of
Aβ(M1-40) and β2m with the nanogel. Moreover, the inhibitory ef-
fect is clearly concentration dependent. Addition of nanogel at a con-
centration 0.03 mg/mL is needed in order to see a signiﬁcant effect.
This is the ﬁrst concentration tested above the cac or cmc equal to
0.01 mg/mL, which corresponds to the self-assembly of the amphi-
philic monomers of MVC16-31-20 and to the formation of the mannan
nanogel.
So far studies indicate that it is the composition of nanoparticles
and their surface characteristics that determine their impact on
ﬁbrillogenesis [45]. The mannan nanogel acts as artiﬁcial chaperones
to inhibit the formation of Aβ(M1-40) and β2m ﬁbrils. Hydrophobicity
and hydrogen bonding between Aβ(M1-40) or β2m and mannan
nanogel, through their hydrophobic domains and polar groups of poly-
mer backbone, respectively, may play a role in binding and/or
preventing the nucleation and elongation of the ﬁbrils. The present
study was performed using pure Aβ(M1-40) or β2m without competi-
tion from other proteins for binding to the nanoparticle surface, which
are conditions dissimilar to those in vivo in terms of salts, metabolites
and biological membranes, and unlike any realistic clinical situation.
Still, systematic investigation in vitro of the aggregation process shows
evidence of a retardation effect of mannan nanogel in ﬁbrillation, an ex-
traordinary hint of its biosafety and promising biomedical applicability.
4. Conclusions
The corona around nanogel is quite speciﬁc and simple, and contains
a small number of proteins including apolipoproteins B-100, A-I and E,
and HSA. The protein corona evolves over time and is formed through
a slow process, and the equilibrium is reached only after ca. 24 h. Inter-
action with the mannan nanogel leads to an increased or unchangedα-
helical structure for apoA-I and HSA, respectively. After binding of HSA
to the nanogel, the environment around the tryptophan side chains is
more hydrophobic. Moreover, blood coagulation is unperturbed and
Aβ(M1-40) and β2m ﬁbrillation is retarded by mannan nanogel
suggesting biosafety, which is mandatory for nanomaterials to be used
in biomedical applications.
Supplementary related to this article can be found online at
doi:10.1016/j.bbagen.2012.04.015.
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